MedTrace Logo

Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBC

NCT04897763 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-01-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250) as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT radiopharmaceutical for the imaging of Non-muscle-invasive bladder cancer (NMIBC) patients.

Conditions

Interventions

DRUG

89Zr-TLX250

89Zr-TLX250 (89Zr-girentuximab) PET/CT performed for all aptients

Sponsors & Collaborators

  • ATONCO

    collaborator UNKNOWN

  • Institut Cancerologie de l'Ouest

    lead OTHER

Principal Investigators

  • Caroline ROUSSEAU, MD, PhD · Institut de Cancerologie de l'Ousest - ICO

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2022-08-24
Completion
2022-09-26

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04897763 on ClinicalTrials.gov